AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...